Advertisement

Efficacy and Safety of Tocilizumab in the Treatment of Ocular Manifestations in Giant Cell Arteritis

  • Nooran Badeeb
    Correspondence
    Corresponding author. University of Jeddah, Hamzah Ibn Al Qasim St, Al Sharafeyah dist, Jeddah 23218, Saudi Arabia.
    Affiliations
    Department of Ophthalmology, University of Jeddah, Jeddah, Saudi Arabia
    Search for articles by this author
  • Rustum Karanjia
    Affiliations
    Doheny Eye Centers, Department of Ophthalmology, David Geffen School of Medicine at UCLA, UCLA Stein Eye Institute, 100 Stein Plaza UCLA, Los Angeles, CA 90095-7000, USA

    Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, Canada

    Doheny Eye Institute, Los Angeles, CA, USA
    Search for articles by this author

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Ophthalmology and Optometry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Yoshifuji H.
        Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy.
        Mod Rheumatol. 2019; 29: 287-293
        • Al-Mousawi A.Z.
        • Gurney S.P.
        • Lorenzi A.R.
        • et al.
        Reviewing the pathophysiology behind the advances in the management of giant cell arteritis.
        Ophthalmol Ther. 2019; https://doi.org/10.6084/m9.figshare.7673285
        • Weyand CM M.
        • Goronzy JJ M.
        Giant cell arteritis and Polymyalgia Rheumatica.
        Ann Intern Med. 2003; 139: 505
        • Vodopivec I.
        • Rizzo J.F.
        Ophthalmic manifestations of giant cell arteritis.
        Rheumatology (United Kingdom). 2018; 57: ii63-ii72
        • Hayreh S.S.
        • Podhajsky P.A.
        • Zimmerman B.
        Ocular manifestations of giant cell arteritis.
        Am J Ophthalmol. 1998; 125: 509-520
        • Hayreh S.S.
        Giant cell arteritis: Its ophthalmic manifestations.
        Indian J Ophthalmol. 2021; 69: 227-235
        • Kleindorfer D.O.
        • Khoury J.
        • Moomaw C.J.
        • et al.
        Stroke incidence is decreasing in whites but not in blacks: a population-based estimate of temporal trends in stroke incidence from the greater cincinnati/northern kentucky stroke study.
        Stroke. 2010; 41: 1326-1331
        • Patil P.
        • Achilleos K.
        • Williams M.
        • et al.
        Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study.
        Clin Exp Rheumatol. 2015; 35 (Available at:) (Accessed November 22, 2013): 246-253
        • Almarzouqi S.J.
        • Morgan M.L.
        • Lee A.G.
        Treatment of giant cell arteritis.
        Curr Opin Ophthalmol. 2015; 26: 469-475
        • Oray M.
        • Abu Samra K.
        • Ebrahimiadib N.
        • et al.
        Long-term side effects of glucocorticoids.
        Expert Opin Drug Saf. 2016; 15: 457-465
        • Stanbury R.M.
        • Graham E.M.
        Systemic corticosteroid therapy - Side effects and their management.
        Br J Ophthalmol. 1998; 82: 704-708
        • Chan C.C.K.
        • Paine M.
        • O’Day J.
        Steroid management in giant cell arteritis.
        Br J Ophthalmol. 2001; 85: 1061-1064
        • Hoffman G.S.
        • Cid M.C.
        • Hellmann D.B.
        • et al.
        A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.
        Arthritis Rheum. 2002; 46: 1309-1318
      1. Jover JA, Cé Sar Herná Ndez-García, Morado IC, Vargas E, et al. Combined Treatment of giant-cell arteritis with methotrexate and prednisone a randomized, double-blind, Placebo-Controlled Trial Background: Corticosteroids Remain the Cornerstone of Therapy.; 2001.Availble at: www.annals.org. Accessed January 16, 2001

        • Mahr A.D.
        • Jover J.A.
        • Spiera R.F.
        • et al.
        Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.
        Arthritis Rheum. 2007; 56: 2789-2797
        • Al-Homood I.A.
        Tocilizumab: a new therapy for large vessel vasculitis.
        Clin Exp Med. 2014; 14: 355-360
        • Rubio-Rivas M.
        • Forero C.G.
        • Mora-Luján J.M.
        • et al.
        Beneficial and harmful outcomes of tocilizumab in severe COVID-19: a systematic review and meta-analysis.
        Pharmacotherapy. 2021; 41: 884-906
        • Stone J.H.
        • Tuckwell K.
        • Dimonaco S.
        • et al.
        Trial of Tocilizumab in Giant-Cell Arteritis.
        N Engl J Med. 2017; 377: 317-328
        • Turesson C.
        • Börjesson O.
        • Larsson K.
        • et al.
        Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis.
        Scand J Rheumatol. 2019; 48: 259-265
        • Christ L.
        • Seitz L.
        • Scholz G.
        • et al.
        OP0061 a proof-of-concept study to assess the efficacy of tocilizumab monotherapy after ultra-short glucocorticoid administration to treat giant cell arteritis - the gusto trial.
        Ann Rheum Dis. 2021; 80: 33.2-33
        • Svasti-Salee C.R.
        • Mollan S.P.
        • Morgan A.W.
        • et al.
        Rapid visual recovery following intravenous tocilizumab in glucocorticoid resistant refractory giant cell arteritis.
        BMJ Case Rep. 2019; 12https://doi.org/10.1136/bcr-2019-229236
        • Vionnet J.
        • Buss G.
        • Mayer C.
        • et al.
        Tocilizumab for giant cell arteritis with corticosteroid-resistant progressive anterior ischemic optic neuropathy.
        Joint Bone Spine. 2017; 84: 615-619
        • Khanna R.K.
        • Hage R.
        • Lecler A.
        • et al.
        Giant cell arteritis with ocular involvement successfully treated with tocilizumab and very short-course glucocorticoids: a case report.
        J Francais d’Ophtalmologie. 2021; 44: 481-484
        • Villiger P.M.
        • Adler S.
        • Kuchen S.
        • et al.
        Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
        Lancet. 2016; 387: 1921-1927
        • Amsler J.
        • Kysela I.
        • Tappeiner C.
        • et al.
        Vision loss in patients with giant cell arteritis treated with tocilizumab.
        Arthritis Res Ther. 2021; 23https://doi.org/10.1186/s13075-021-02480-4
        • Unizony S.
        • McCulley T.J.
        • Spiera R.
        • et al.
        Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations.
        Arthritis Res Ther. 2021; 23https://doi.org/10.1186/s13075-020-02377-8
        • Regola F.
        • Cerudelli E.
        • Bosio G.
        • et al.
        Long-term treatment with tocilizumab in giant cell arteritis: Efficacy and safety in a monocentric cohort of patients.
        Rheumatol Adv Pract. 2020; 4https://doi.org/10.1093/rap/rkaa017
      2. Genentech, Inc. Highlights of prescribing information.
        (Available at:) (Accessed March 3, 2021)
        • Abdallah H.
        • Hsu J.C.
        • Lu P.
        • et al.
        Pharmacokinetic and Pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA.
        J Clin Pharmacol. 2017; 57: 459-468